FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Kraws Jeffrey J					2. Issuer Name and Ticker or Trading Symbol Synthetic Biologics, Inc. [SYN]								(Check	tionship of Reporting Person(s) to Issuer all applicable) Director 10% Owner					
(Last)	(1	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 12/23/2021								_ X	Director Officer (g below)	ve title		Other (sp below)		
C/O SYN	THETIC BIG																		
9605 MEDICAL CENTER DRIVE, SUITE 270					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street)														Form filed	by More	than O	ne Reporting	g Person	
ROCKVIL	LE N	MD	20850																
(City)	(:	State)	(Zip)																
		Ta	able I - Non-D	eriva	tive S	ecuritie	s Ad	cquir	ed, Di	sposed o	f, or Be	nef	icially	Owned					
1. Title of Security (Instr. 3) 2. Trans. Date (Month/I				te		Execution if any	2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Instr.					5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
								Co	ode V	Amount	Amount (A) or (D)		Price	Reported Transactio (Instr. 3 ar	ion(s)			Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
			(e.g	., pu	ts, ca	lls, warr	ants	s, opt	tions,	converti	ble sec	uriti	ies)						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.) 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
				Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Nu	nount or imber of ares		(Instr. 4)				
Stock Options (right to buy)	\$0.3314	12/23/2021		А		200,000 ⁽¹⁾		01/23	/2022 ⁽¹⁾	12/23/2028	Commo Stock	n 20	00,000	\$0	200,0	000	D		

Explanation of Responses:

1. These stock options vest pro rata on a monthly basis over 12 months.

<u>/s/ Jeffrey Kraws</u> <u>12/27/2021</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.